Wednesday, December 9, 2015
San Diego’s Human Longevity Inc. (HLI), a genomics-based, technology-driven company, has acquired Cypher Genomics, a genome informatics company offering human genomic interpretation software solutions. The company has 14 employees who will join HLI, including Cypher CEO and co-founder Ashley Van Zeeland, Ph.D., who now is the head of HLI’s pediatric business. Financial details of the deal were not disclosed.
Teva Pharmaceutical Industries and Heptares Therapeutics, a wholly owned subsidiary of Sosei Group, have entered into a licensing and drug-discovery agreement under which Teva will receive exclusive global rights to develop, manufacture and commercialize novel, small-molecule calcitonin gene-related peptide (CGRP) antagonists discovered by Heptares for the treatment of migraine headaches.
Pfizer and Allergan have entered into a definitive merger agreement in a stock transaction currently valued at $363.63 per Allergan share, for a total enterprise value of about $160 billion, based on the closing price of Pfizer common stock of $32.18 on Nov. 20. The transaction represents more than a 30% premium based on Pfizer’s and Allergan’s unaffected share prices as of Oct. 28. Allergan shareholders will receive 11.3 shares of the combined company for each of their Allergan shares, and Pfizer stockholders will receive one share of the combined company for each of their Pfizer shares.
Mylan Laboratories, a subsidiary of Mylan, has successfully completed the acquisition of certain women’s healthcare businesses, now known as Jai Pharma, which were spun off from Famy Care. The transaction brings Mylan a broad women’s care portfolio, strong technical capabilities and dedicated hormone manufacturing, which, when combined with Mylan’s expansive global commercial footprint and supply chain infrastructure, will create a leading women’s healthcare franchise.